Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents

Not Applicable

Terminated

Conditions: Insulin Resistance
Obesity

Interventions: Dietary Supplement: Sucrose
Dietary Supplement: Sucralose + maltodextrin
Dietary Supplement: Sucralose

First Posted Date: 2015-07-16

Last Posted Date: 2018-01-17

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT02499705

Locations: 🇺🇸
The John B. Pierce Laboratory, New Haven, Connecticut, United States

Melatonin Treatment for Night-Eating Syndrome

Not Applicable

Terminated

Conditions: Night-eating Syndrome

Interventions: Dietary Supplement: Melatonin
Other: Placebo

First Posted Date: 2015-07-16

Last Posted Date: 2018-01-23

Lead Sponsor: Yale University

Target Recruit Count: 2

Registration Number: NCT02500017

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Does Sweet Taste Potentiate Nicotine Cue Reactivity?

Phase 1

Completed

Conditions: Healthy

Interventions: Device: flavor and sweetener
Device: flavor, nicotine and sweetener
Device: flavor
Device: flavor and nicotine

First Posted Date: 2015-07-16

Last Posted Date: 2020-03-09

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT02499757

Locations: 🇺🇸
The John B Pierce Laboratory, New Haven, Connecticut, United States

Short Term Effects of Electronic Cigarettes in Tobacco Dependent Adults

Not Applicable

Completed

Conditions: Smoking
Nicotine Dependence

Interventions: Other: Non-nicotine e-cigarette
Other: Nicotine e-cigarette

First Posted Date: 2015-07-15

Last Posted Date: 2017-07-02

Lead Sponsor: Yale University

Target Recruit Count: 40

Registration Number: NCT02498145

Locations: 🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: CDX-1401
Drug: MPDL3280A

First Posted Date: 2015-07-13

Last Posted Date: 2017-06-22

Lead Sponsor: Yale University

Registration Number: NCT02495636

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Ultrasound-guided Continuous Proximal Adductor Canal vs Continuous Femoral Nerve Block for Postoperative Pain Control and Rehabilitation Following Total Knee Arthroplasty

Not Applicable

Withdrawn

Conditions: Total Knee Arthroplasty

Interventions: Procedure: Continuous proximal adductor canal block
Procedure: Continuous femoral nerve block

First Posted Date: 2015-07-13

Last Posted Date: 2016-12-09

Lead Sponsor: Yale University

Registration Number: NCT02495805

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Phase 2

Recruiting

Conditions: HER2/Neu+ Uterine Serous Carcinoma

Interventions: Drug: Afatinib

First Posted Date: 2015-07-07

Last Posted Date: 2024-08-20

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT02491099

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: MEDI4736

First Posted Date: 2015-07-03

Last Posted Date: 2022-10-26

Lead Sponsor: Yale University

Target Recruit Count: 68

Registration Number: NCT02489448

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Gaze Modification Strategies for Toddlers With Autism Spectrum Disorder

Not Applicable

Completed

Conditions: Autism Spectrum Disorder

Interventions: Other: Gaze-contingent eye-tracking technology

First Posted Date: 2015-07-02

Last Posted Date: 2020-03-06

Lead Sponsor: Yale University

Target Recruit Count: 81

Registration Number: NCT02488226

Locations: 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States

Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects

Phase 2

Completed

Conditions: Depression

Interventions: Drug: Ketamine
Drug: sirolimus
Drug: Placebo

First Posted Date: 2015-07-01

Last Posted Date: 2020-07-16

Lead Sponsor: Yale University

Target Recruit Count: 23

Registration Number: NCT02487485

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
West Haven Veterans Affairs, West Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy